ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1789941
CHEMBL1789941
Compound Name RUXOLITINIB
ChEMBL Synonyms JAKAVI | JAKAFI | INCB-018424 | RUXOLITINIB PHOSPHATE | RUXOLITINIB | INCB018424 SALT
Max Phase 4 (Approved)
Trade Names JAKAFI | JAKAVI
Molecular Formula C17H18N6

Additional synonyms for CHEMBL1789941 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES N#CC[C@H](C1CCCC1)n2cc(cn2)c3ncnc4[nH]ccc34
Standard InChI InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23) ...
Download InChI
Standard InChI Key HFNKQEVNSGCOJV-OAHLLOKOSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1789941

Molecule Features

CHEMBL1789941 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:Y Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Tyrosine-protein kinase JAK1 inhibitor Tyrosine-protein kinase JAK1 FDA
Tyrosine-protein kinase JAK2 inhibitor Tyrosine-protein kinase JAK2 FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Alopecia AreataD000506EFO:0004192alopecia areata2ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma2ClinicalTrials
Hodgkin DiseaseD006689EFO:0000183Hodgkins lymphoma2ClinicalTrials
LeukemiaD007938EFO:0000565leukemia2ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveD015464EFO:0000339chronic myelogenous leukemia1ClinicalTrials
Pancreatic NeoplasmsD010190EFO:0002618pancreatic carcinoma3ClinicalTrials
Inflammatory Breast NeoplasmsD058922EFO:1000984inflammatory breast carcinoma2ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma2ClinicalTrials
Carcinoma, Squamous CellD002294EFO:0000181head and neck squamous cell carcinoma2ClinicalTrials
Dermatitis, AtopicD003876EFO:0000274atopic eczema2ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-CellD015451EFO:0000095chronic lymphocytic leukemia2ClinicalTrials
Primary MyelofibrosisD055728EFO:0002430primary myelofibrosis4ClinicalTrials
DailyMed
HIV InfectionsD015658EFO:0000764HIV infection2ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma2ClinicalTrials
Thrombocythemia, EssentialD013920EFO:0000479essential thrombocythemia2ClinicalTrials
VitiligoD014820EFO:0004208Vitiligo2ClinicalTrials
Arthritis, RheumatoidD001172EFO:0000685rheumatoid arthritis2ClinicalTrials
Myeloproliferative DisordersD009196EFO:0004251myeloproliferative disorder3ClinicalTrials
CachexiaD002100HP:0004326cachexia2ClinicalTrials
Graft vs Host DiseaseD006086EFO:0004599acute graft vs. host disease3ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia2ClinicalTrials
LymphomaD008223EFO:0000574lymphoma2ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC
Polycythemia VeraD011087EFO:0002429polycythemia vera4DailyMed
ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-LymphomaD054198EFO:0000220acute lymphoblastic leukemia2ClinicalTrials
Colorectal NeoplasmsD015179EFO:1001951colorectal carcinoma2ClinicalTrials
Lung NeoplasmsD008175EFO:0001071lung carcinoma1ClinicalTrials
PsoriasisD011565EFO:0000676psoriasis2ClinicalTrials
beta-ThalassemiaD017086Orphanet:231214Beta-thalassemia major2ClinicalTrials
Lymphoma, Non-HodgkinD008228EFO:0005952non-Hodgkins lymphoma1ClinicalTrials

Clinical Data

ClinicalTrials.gov RUXOLITINIB
The Cochrane Collaboration RUXOLITINIB

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1789941. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL2148 Tyrosine-protein kinase JAK3 Homo sapiens 1.000
CHEMBL2971 Tyrosine-protein kinase JAK2 Homo sapiens 1.000
CHEMBL2835 Tyrosine-protein kinase JAK1 Homo sapiens 1.000
CHEMBL3553 Tyrosine-protein kinase TYK2 Homo sapiens 1.000
CHEMBL1075104 Leucine-rich repeat serine/threonine-protein kinase 2 Homo sapiens 0.509
CHEMBL5608 NT-3 growth factor receptor Homo sapiens 0.243



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL2148 Tyrosine-protein kinase JAK3 Homo sapiens 1.000
CHEMBL2971 Tyrosine-protein kinase JAK2 Homo sapiens 1.000
CHEMBL2835 Tyrosine-protein kinase JAK1 Homo sapiens 1.000
CHEMBL3553 Tyrosine-protein kinase TYK2 Homo sapiens 1.000
CHEMBL4576 Homeodomain-interacting protein kinase 2 Homo sapiens 0.994
CHEMBL1075104 Leucine-rich repeat serine/threonine-protein kinase 2 Homo sapiens 0.898
CHEMBL5608 NT-3 growth factor receptor Homo sapiens 0.881
CHEMBL2553 Ribosomal protein S6 kinase alpha 1 Homo sapiens 0.876
CHEMBL5330 Mitogen-activated protein kinase kinase kinase kinase 2 Homo sapiens 0.876
CHEMBL1908385 Serine/threonine-protein kinase pknB Mycobacterium tuberculosis 0.841
CHEMBL5941 Serine/threonine-protein kinase MST4 Homo sapiens 0.744
CHEMBL4924 Ribosomal protein S6 kinase alpha 6 Homo sapiens 0.719
CHEMBL5476 Bone morphogenetic protein receptor type-1B Homo sapiens 0.695
CHEMBL5698 NUAK family SNF1-like kinase 2 Homo sapiens 0.671
CHEMBL5914 Mitogen-activated protein kinase kinase kinase 2 Homo sapiens 0.518
CHEMBL5427 Homeodomain-interacting protein kinase 1 Homo sapiens 0.399
CHEMBL6191 SPS1/STE20-related protein kinase YSK4 Homo sapiens 0.379
CHEMBL4577 Homeodomain-interacting protein kinase 3 Homo sapiens 0.314
CHEMBL1957 Insulin-like growth factor I receptor Homo sapiens 0.309
CHEMBL3268 PI4-kinase beta subunit Homo sapiens 0.286

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
306.4 306.1593 3.47 4 83.18 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
5 1 0 6 1 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
11.63 3.67 2.07 2.07 3 23 0.8

Structural Alerts

There are no structural alerts for CHEMBL1789941

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XE - Protein kinase inhibitors
L01XE18 - ruxolitinib

ChemSpider ChemSpider:HFNKQEVNSGCOJV-OAHLLOKOSA-N
DailyMed ruxolitinib phosphate
Wikipedia Ruxolitinib

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1789941



BindingDB 50355501
Brenda 19116 39793
ChEBI 66919
ChemicalBook CB02499581
DrugBank DB08877
DrugCentral 4190
EPA CompTox Dashboard DTXSID10240930
FDA SRS 82S8X8XX8H
Guide to Pharmacology 5688
IBM Patent System C11C8D6D928559ACF7A336AA8533C9A9
LINCS LSM-1139
MolPort MolPort-046-196-087 MolPort-020-006-045
Nikkaji J2.740.099J
PDBe RXT
PharmGKB PA166123386
PubChem 25126798
PubChem: Thomson Pharma 81071277
Selleck INCB18424
SureChEMBL SCHEMBL16546708 SCHEMBL171319
ZINC ZINC000043207851

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/HFNKQEVNSGCOJV-OAHLLOKOSA-N spacer
spacer